Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1309446

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1309446

Asia Pacific Fibromyalgia Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Anticonvulsants, Antidepressants, Muscle Relaxants and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

PUBLISHED:
PAGES: 83 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Asia Pacific Fibromyalgia Treatment Market would witness market growth of 5.2% CAGR during the forecast period (2023-2030).

Fibromyalgia (FM) is a somatization illness characterized by widespread, persistent musculoskeletal pain in addition to impacting the patient's quality of life. The symptoms also affect the patient's emotional condition because the only indication of the sickness is a pain in the whole body. Among the functional issues that frequently coexist with FM are depression, panic attacks, irritable bowel syndrome, chronic fatigue syndrome, anxiety, and post-traumatic stress disorder. Fibromyalgia is commonly categorized as a pain control disorder because it is a central sensitization problem.

FM is believed to be caused by sensitization, which encompasses systemic symptoms including cognitive decline, sleep issues, anxiety, tiredness, and depressive episodes, as well as central sensitivity syndromes like joint stiffness and chronic pain at multiple painful places. Many ailments, including infections, mental or neurological disorders, diabetes, and rheumatic pathologies, are usually connected to FM. Moreover, despite proof for a specific candidate gene, numerous studies have suggested a genetic predisposition for fibromyalgia.

The remarkable rise in human longevity throughout the 20th century has manifested in the region phenomenon of population aging. India's population over 60 has more than quadrupled in the past 50 years. According to the 2011 census, the number of elderly persons (60+ years) was 103.83 million; this number is expected to rise to 133.32 million in 2021, 178.59 million in 2031, 236.01 million in 2041, and 300.96 million in 2051. Considering that musculoskeletal disorders like fibromyalgia are typically more prevalent in the elderly, the growing geriatric population and the government's approach to ensuring the welfare of the elderly will increase the demand and purchasing power of the population in the region, thereby driving market growth in APAC.

The China market dominated the Asia Pacific Fibromyalgia Treatment Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $302.6 million by 2030. The Japan market is exhibiting a CAGR of 4.5% during (2023 - 2030). Additionally, The India market would register a CAGR of 5.8% during (2023 - 2030).

Based on Drug Class, the market is segmented into Anticonvulsants, Antidepressants, Muscle Relaxants and Others. Based on Distribution Channel, the market is segmented into Drug stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Anticonvulsants
  • Antidepressants
  • Muscle Relaxants
  • Others

By Distribution Channel

  • Drug stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled

  • AbbVie, Inc.
  • Novartis AG
  • Eli Lilly And Company
  • Amneal Pharmaceuticals, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Lupin Limited
  • Abbott Laboratories
  • Viatris, Inc.
  • Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Asia Pacific Fibromyalgia Treatment Market, by Drug Class
    • 1.4.2 Asia Pacific Fibromyalgia Treatment Market, by Distribution Channel
    • 1.4.3 Asia Pacific Fibromyalgia Treatment Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition & scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Asia Pacific Fibromyalgia Treatment Market by Drug Class

  • 3.1 Asia Pacific Anticonvulsants Market by Country
  • 3.2 Asia Pacific Antidepressants Market by Country
  • 3.3 Asia Pacific Muscle Relaxants Market by Country
  • 3.4 Asia Pacific Others Market by Country

Chapter 4. Asia Pacific Fibromyalgia Treatment Market by Distribution Channel

  • 4.1 Asia Pacific Drug stores & Retail Pharmacies Market by Country
  • 4.2 Asia Pacific Hospital Pharmacies Market by Country
  • 4.3 Asia Pacific Online Providers Market by Country

Chapter 5. Asia Pacific Fibromyalgia Treatment Market by Country

  • 5.1 China Fibromyalgia Treatment Market
    • 5.1.1 China Fibromyalgia Treatment Market by Drug Class
    • 5.1.2 China Fibromyalgia Treatment Market by Distribution Channel
  • 5.2 Japan Fibromyalgia Treatment Market
    • 5.2.1 Japan Fibromyalgia Treatment Market by Drug Class
    • 5.2.2 Japan Fibromyalgia Treatment Market by Distribution Channel
  • 5.3 India Fibromyalgia Treatment Market
    • 5.3.1 India Fibromyalgia Treatment Market by Drug Class
    • 5.3.2 India Fibromyalgia Treatment Market by Distribution Channel
  • 5.4 South Korea Fibromyalgia Treatment Market
    • 5.4.1 South Korea Fibromyalgia Treatment Market by Drug Class
    • 5.4.2 South Korea Fibromyalgia Treatment Market by Distribution Channel
  • 5.5 Singapore Fibromyalgia Treatment Market
    • 5.5.1 Singapore Fibromyalgia Treatment Market by Drug Class
    • 5.5.2 Singapore Fibromyalgia Treatment Market by Distribution Channel
  • 5.6 Malaysia Fibromyalgia Treatment Market
    • 5.6.1 Malaysia Fibromyalgia Treatment Market by Drug Class
    • 5.6.2 Malaysia Fibromyalgia Treatment Market by Distribution Channel
  • 5.7 Rest of Asia Pacific Fibromyalgia Treatment Market
    • 5.7.1 Rest of Asia Pacific Fibromyalgia Treatment Market by Drug Class
    • 5.7.2 Rest of Asia Pacific Fibromyalgia Treatment Market by Distribution Channel

Chapter 6. Company Profiles

  • 6.1 Abbott Laboratories
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 SWOT Analysis
  • 6.2 AbbVie, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Regional Analysis
    • 6.2.4 Research & Development Expense
    • 6.2.5 Recent strategies and developments:
      • 6.2.5.1 Acquisition and Mergers:
  • 6.3 Novartis AG
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expense
    • 6.3.5 Recent strategies and developments:
      • 6.3.5.1 Acquisition and Mergers:
  • 6.4 Eli Lilly And Company
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expenses
  • 6.5 Amneal Pharmaceuticals, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental Analysis
    • 6.5.4 Research & Development Expenses
  • 6.6 Teva Pharmaceutical Industries Ltd.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Regional Analysis
    • 6.6.4 Research & Development Expenses
  • 6.7 Zydus Lifesciences Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Segmental and Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Trials and Approvals:
  • 6.8 Lupin Limited
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Recent strategies and developments:
      • 6.8.3.1 Trials and Approvals:
  • 6.9 Viatris, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental Analysis
    • 6.9.4 Research & Development Expense
  • 6.10. Sun Pharmaceutical Industries Ltd.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Regional Analysis
    • 6.10.4 Research & Development Expenses

LIST OF TABLES

  • TABLE 1 Asia Pacific Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 2 Asia Pacific Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 3 Asia Pacific Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 4 Asia Pacific Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 5 Asia Pacific Anticonvulsants Market by Country, 2019 - 2022, USD Million
  • TABLE 6 Asia Pacific Anticonvulsants Market by Country, 2023 - 2030, USD Million
  • TABLE 7 Asia Pacific Antidepressants Market by Country, 2019 - 2022, USD Million
  • TABLE 8 Asia Pacific Antidepressants Market by Country, 2023 - 2030, USD Million
  • TABLE 9 Asia Pacific Muscle Relaxants Market by Country, 2019 - 2022, USD Million
  • TABLE 10 Asia Pacific Muscle Relaxants Market by Country, 2023 - 2030, USD Million
  • TABLE 11 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 12 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 13 Asia Pacific Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 14 Asia Pacific Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 15 Asia Pacific Drug stores & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 16 Asia Pacific Drug stores & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
  • TABLE 17 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 18 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
  • TABLE 19 Asia Pacific Online Providers Market by Country, 2019 - 2022, USD Million
  • TABLE 20 Asia Pacific Online Providers Market by Country, 2023 - 2030, USD Million
  • TABLE 21 Asia Pacific Fibromyalgia Treatment Market by Country, 2019 - 2022, USD Million
  • TABLE 22 Asia Pacific Fibromyalgia Treatment Market by Country, 2023 - 2030, USD Million
  • TABLE 23 China Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 24 China Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 25 China Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 26 China Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 27 China Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 28 China Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 29 Japan Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 30 Japan Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 31 Japan Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 32 Japan Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 33 Japan Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 34 Japan Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 35 India Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 36 India Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 37 India Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 38 India Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 39 India Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 40 India Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 41 South Korea Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 42 South Korea Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 43 South Korea Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 44 South Korea Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 45 South Korea Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 46 South Korea Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 47 Singapore Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 48 Singapore Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 49 Singapore Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 50 Singapore Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 51 Singapore Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 52 Singapore Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 53 Malaysia Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 54 Malaysia Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 55 Malaysia Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 56 Malaysia Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 57 Malaysia Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 58 Malaysia Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 59 Rest of Asia Pacific Fibromyalgia Treatment Market, 2019 - 2022, USD Million
  • TABLE 60 Rest of Asia Pacific Fibromyalgia Treatment Market, 2023 - 2030, USD Million
  • TABLE 61 Rest of Asia Pacific Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 62 Rest of Asia Pacific Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
  • TABLE 63 Rest of Asia Pacific Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 64 Rest of Asia Pacific Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
  • TABLE 65 Key Information - Abbott Laboratories
  • TABLE 66 Key information - AbbVie, Inc.
  • TABLE 67 Key Information - Novartis AG
  • TABLE 68 Key Information - Eli Lilly And Company
  • TABLE 69 Key Information - Amneal Pharmaceuticals, INc.
  • TABLE 70 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 71 Key Information - Zydus Lifesciences Ltd.
  • TABLE 72 Key Information - Lupin Limited
  • TABLE 73 key information - Viatris, Inc.
  • TABLE 74 Key Information - Sun Pharmaceutical Industries Ltd.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Asia Pacific Fibromyalgia Treatment Market share by Drug Class, 2022
  • FIG 3 Asia Pacific Fibromyalgia Treatment Market share by Drug Class, 2030
  • FIG 4 Asia Pacific Fibromyalgia Treatment Market by Drug Class, 2019 - 2030, USD Million
  • FIG 5 Asia Pacific Fibromyalgia Treatment Market share by Distribution Channel, 2022
  • FIG 6 Asia Pacific Fibromyalgia Treatment Market share by Distribution Channel, 2030
  • FIG 7 Asia Pacific Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2030, USD Million
  • FIG 8 Asia Pacific Fibromyalgia Treatment Market share by Country, 2022
  • FIG 9 Asia Pacific Fibromyalgia Treatment Market share by Country, 2030
  • FIG 10 Asia Pacific Fibromyalgia Treatment Market by Country, 2019 - 2030, USD Million
  • FIG 11 Swot analysis: Abbott laboratories
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!